A number of firms have modified their ratings and price targets on shares of MacroGenics (NASDAQ: MGNX) recently:

  • 9/11/2017 – MacroGenics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $44.00 price target on the stock.
  • 9/1/2017 – MacroGenics was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 9/1/2017 – MacroGenics had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $26.00 price target on the stock.
  • 8/25/2017 – MacroGenics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 8/12/2017 – MacroGenics was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/7/2017 – MacroGenics had its price target lowered by analysts at Morgan Stanley from $22.00 to $21.00. They now have an “equal weight” rating on the stock.
  • 8/4/2017 – MacroGenics had its “buy” rating reaffirmed by analysts at Cowen and Company.
  • 8/3/2017 – MacroGenics was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 8/3/2017 – MacroGenics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “
  • 7/31/2017 – MacroGenics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/18/2017 – MacroGenics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. They now have a $19.00 price target on the stock. According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “

Shares of MacroGenics, Inc. (NASDAQ MGNX) traded down 3.80% during mid-day trading on Monday, reaching $18.22. 178,104 shares of the company traded hands. The company’s market capitalization is $670.46 million. The stock’s 50-day moving average is $17.01 and its 200-day moving average is $18.45. MacroGenics, Inc. has a 52 week low of $14.36 and a 52 week high of $32.68.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by $0.09. The firm had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $15.82 million. MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The business’s quarterly revenue was down 97.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.12 earnings per share. On average, equities analysts predict that MacroGenics, Inc. will post ($4.42) EPS for the current fiscal year.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Receive News & Stock Ratings for MacroGenics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc and related stocks with our FREE daily email newsletter.